Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer

Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer

December 17, 2021

Aerie Pharmaceuticals announced that Raj Kannan will join the company as Chief Executive Officer and a director, effective December 20, 2021.

“On behalf of the Board of Directors, I am very pleased to welcome Raj Kannan to Aerie. During the search process, the Board was pleased to interview several strong candidates and Raj rose to the top of the list during the process. Raj brings a track record of building effective organizations and teams, launching and growing products in the U.S.,” said Benjamin F. McGraw, III, Pharm.D., Executive Chairman of the Board of Directors.

“With a strong commercial franchise in glaucoma, solid research and development foundation and a pipeline led by two phase 3 ready programs, Aerie is poised to fulfill its goal of becoming a leading ophthalmology company under Raj’s thoughtful and strategic leadership.”

“The Aerie team has built an impressive ophthalmology company with an exciting glaucoma franchise that is global in reach and an exciting pipeline of product development candidates that has the potential to create significant value,” said Mr. Kannan.

"I am honored to have this opportunity to lead the company and work with this team to deliver on our commercial prospects and realize the full promise of our pipeline,” he added.

Raj Kannan has over 25 years of experience as a leader and developer of businesses. He has successfully led and expanded organizations, as well as supported many successful launches in a variety of therapeutic areas in the United States and around the world.

Mr. Kannan was formerly the CEO and President of Chiasma, Inc., where he guided the company through the approval and marketing of the first oral medication for patients with acromegaly in over a decade, as well as its acquisition by Amryt Pharma Plc.

Raj Kannan was previously the Chief Commercial Officer of Kiniksa Pharmaceuticals, where he built the company's commercial activities, which included sales, marketing, and business analytics. Prior to joining Kiniksa, Raj worked at Merck KGaA as the Global Head of the Neurology and Immunology Business Franchise.

He was in charge of transforming the company's largest franchise into a growing franchise with annual revenues of $2 billion by making significant strategic investment shifts to support new product introductions and recalibrating pipeline investments.

Mr. Kannan previously worked for Boehringer Ingelheim International GmbH in the United States, Canada, and Germany for eleven years, including as Global Marketing Head of the Cardiovascular Franchise, where he was responsible for over $3.5 billion in yearly revenues. Raj presently serves on the board of directors of Amryt Pharma Plc as a non-executive director.